Verteporfin

New Drug Approvals

Visudyne, Verteporfin, Verteporfina, Verteporfine, Verteporfinum, Visudine, BPD verteporfin

Molecular Formula: C₄₁H₄₂N₄O₈

Molecular Weight: 718.79418 g/mol

129497-78-5

Benzoporphyrin derivative monoacid ring A

BPD-MA
CL-315555/CL-315585
CL-318952
CV-001

18-ethenyl-4,4a-dihydro-3,4-bis(methoxycarbonyl)-4a,8,14,19-tetramethyl-23H,25H-benzo(b)porphine-9,13-dipropanoic acid monomethyl ester

US5798349; 5770619; 5756541; 5707608 (from FDA Orange Book)

For the treatment of patients with predominantly classic subfoveal choroidal neovascularization due to age-related macular degeneration, pathologic myopia or presumed ocular histoplasmosis syndrome. Verteporfin can also be used to destroy tumors.

THESIS…………http://etd.lsu.edu/docs/available/etd-11152013-105517/unrestricted/jinadasadiss.pdf  AND https://hydra.hull.ac.uk/assets/hull:4695a/content

Verteporfin (trade name Visudyne), a benzoporphyrin derivative, is a medication used as a photosensitizer for photodynamic therapy to eliminate the abnormal blood vessels in the eye associated with conditions such as the wet form of macular degeneration. Verteporfin accumulates in these abnormal blood vessels and, when stimulated by nonthermal red light with awavelength of 693 nm in the presence of oxygen, produces highly…

View original post 1,043 more words